Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease ...

If you continue to have this issue please contact [email protected]. GLP-1 receptor agonist use before pregnancy was tied to lower risks for hypertensive disorders of pregnancy and ...

Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.

Nearly half of patients with type 2 diabetes and two-thirds without discontinue GLP-1 receptor agonists within a year, with weight loss, income, and adverse events influencing discontinuation and ...

Share on Pinterest Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists. Image credit: Kathryn Gamble for The Washington Post via Getty Images. Diabetes ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...

Helix, a leader in precision health, is unveiling a new comprehensive clinico-genomic dataset of over 15,000 patients treated with glucagon-like-peptide-1 (GLP-1) agonists including semaglutide, ...

DD01 is a liver-targeted, long-acting, dual GLP-1/glucagon receptor agonist previously shown to rapidly resolve hepatic steatosis, improve glycemic control, and reduce body weight in subjects with ...